---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-001174"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T04:16:09.011143+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics granted US patent covering IV levosimendan for PH-HFpEF until 2040

## Summary
- USPTO Notice of Allowance for patent covering IV levosimendan in PH-HFpEF; patent expected to last until 2040.
- No FDA-approved treatments exist for PH-HFpEF, which affects over 1.5 million patients in the US.
- HELP Study showed levosimendan improved 6-minute walk distance by 29 meters (p=0.03); FDA accepted endpoint for Phase 3.
- Patent builds on existing U.S. Patent No. 11,213,524 for subcutaneous levosimendan issued Jan 2022.

## SEC filing metadata
- accession: 0001654954-23-001174
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495423001174/0001654954-23-001174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495423001174/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-001174
- JSON: https://secwatch.observer/filing/0001654954-23-001174.json
- Plain text: https://secwatch.observer/filing/0001654954-23-001174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.